BioSpace News Archive

Surface Oncology today reported financial results and corporate highlights for the fourth quarter and full year 2022, as well as anticipated near-term corporate milestones.

Foghorn® Therapeutics Inc. today provided a corporate update including the Company’s 2023 strategic priorities and 2022 key achievements in conjunction with its 10-K filing for the year ending December 31, 2022.

Fulcrum Therapeutics, Inc. today reported financial results for the fourth quarter and full year 2022 and provided a business update, including on FTX-6058.

BioXcel Therapeutics, Inc today announced its financial results for the fourth quarter and full year ended Dec. 31, 2022 and provided an update on key strategic initiatives.

Akebia Therapeutics®, Inc. today reported financial results for the fourth quarter and full-year ended December 31, 2022 and provided business highlights.

Palvella Therapeutics, Inc. today announced positive topline results from the Company’s Phase 2 study of QTORIN™ rapamycin in Microcystic Lymphatic Malformations (Microcystic LM). Microcystic LM is a rare, chronically debilitating genetic disease caused by dysregulation of the PI3K/mTOR pathway.

Arch Therapeutics, Inc. today announced that the Centers for Medicare and Medicaid Services (“ CMS ”) established a new Level II Healthcare Common Procedure Coding System (“HCPCS ”) code dedicated to the Company’s AC5 ® Advanced Wound System (“ AC5 ”).

LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J. Oliger to its board of directors effective March 9, 2023.

Gain Therapeutics, Inc. today announced that Matthias Alder, Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference, taking place March 14-16 online.

Vaccinex, Inc. (Nasdaq: VCNX) today reported that it has enrolled 36 subjects in the open-label, Phase 1b/2 KEYNOTE-B84 study (NCT04815720) to evaluate first line therapy of pepinemab in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, in immunotherapy naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).